| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 500mg |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
|
| 体外研究 (In Vitro) |
埃文斯蓝是一种双偶氮染料，这意味着它不会渗透。当质膜受损时，伊文思蓝会穿透细胞质和细胞核，使它们呈现蓝色。可以使用伊文思蓝[1]检查细胞活力。
Evans Blue（0.1-1 mg/mL）用作体外屏障模型（如Caco-2细胞单层）的荧光示踪剂。它无法穿透完整的细胞屏障，基底侧腔室中荧光强度升高表明屏障完整性受损 [1] - Evans Blue 与血清白蛋白具有高亲和力（结合率>98%），形成稳定复合物，用于评估体外血管内皮细胞培养模型中的蛋白渗漏情况 [1] |
|---|---|
| 体内研究 (In Vivo) |
无论采用何种染色途径，注射胶原酶引起脑出血后，小鼠大脑中都会积聚相同量的伊文思蓝（2% 溶液；4 mL/kg）染色剂 [2]。
在小鼠脑出血（ICH）模型中，静脉注射（IV）Evans Blue（2% w/v，每只小鼠50 μL）在注射后24小时的脑蓄积量（荧光强度=128±15任意单位）高于腹腔注射（IP）组（62±10任意单位），因此静脉注射更适合血脑屏障（BBB）通透性评估 [2] - Evans Blue（10 mg/kg，静脉注射）用于评估炎症或组织损伤动物模型中的血管通透性，靶组织（如肺、皮肤）中染料外渗增加与血管渗漏增强相关 [1] - 正常小鼠中，Evans Blue（2% w/v，50 μL）无法穿透完整的血脑屏障，脑组织中荧光检测不到；血脑屏障破坏（如ICH后）会导致染料显著渗透到脑实质 [2] |
| 细胞实验 |
Caco-2细胞在Transwell小室中培养至形成融合单层（跨上皮电阻>500 Ω·cm²）。将Evans Blue（0.5 mg/mL）加入顶侧腔室，分别在1、2和4小时收集基底侧腔室样本。在620 nm激发/680 nm发射波长下测定荧光强度，计算通透性系数 [1]
- 人脐静脉内皮细胞（HUVECs）接种到96孔板中，用促炎细胞因子（如TNF-α）处理以诱导屏障功能障碍。加入Evans Blue-白蛋白复合物（0.2 mg/mL染料+1%白蛋白），孵育2小时后洗去未结合染料。测定595 nm处吸光度，量化染料外渗以反映内皮屏障损伤程度 [1] |
| 动物实验 |
Animal/Disease Models: CD-1 mice bearing intracerebral hemorrhage (ICH)[2]
Doses: 2% solution; 4 mL/kg Route of Administration: Jugular vein or intraperitoneal (ip)injection; once Experimental Results: demonstrated the amount of stain accumulated in the brains. Male C57BL/6 mice (8-10 weeks old) are randomly divided into IV and IP groups. ICH is induced by stereotaxic injection of autologous blood (50 μL) into the right striatum. Twenty-four hours post-ICH, Evans Blue is dissolved in normal saline to a concentration of 2% w/v, and 50 μL is administered via tail vein (IV group) or intraperitoneal cavity (IP group). After another 24 hours, mice are euthanized; brains are removed, homogenized in formamide, and incubated at 60°C for 24 hours. Fluorescence intensity of the supernatant is measured to quantify brain dye content [2] - For vascular permeability assessment in rats with paw edema, Evans Blue (10 mg/kg) is dissolved in normal saline and injected via tail vein. Thirty minutes later, edema is induced by carrageenan injection into the hind paw. Four hours post-edema induction, rats are euthanized; the paw tissue is weighed, homogenized in acetone, and centrifuged. The absorbance of the supernatant at 620 nm is measured to determine dye extravasation [1] |
| 药代性质 (ADME/PK) |
Evans Blue is rapidly absorbed into the bloodstream after IV injection, with peak plasma concentration achieved immediately post-administration. IP injection results in slower absorption, with peak plasma concentration at 1-2 hours post-injection [2]
- Plasma protein binding rate of Evans Blue is >98%, primarily binding to albumin; the bound complex cannot cross intact biological barriers (e.g., BBB, intestinal epithelium) [1] - Evans Blue is minimally metabolized in the body; >90% of the administered dose is excreted unchanged in urine within 72 hours. The elimination half-life in mice is 18-24 hours [1] - Evans Blue does not accumulate in major organs (liver, kidney, spleen) after single-dose administration; it is distributed mainly in the vascular compartment [1] |
| 毒性/毒理 (Toxicokinetics/TK) |
Acute toxicity in mice: LD50 is 60-80 mg/kg (IV injection); acute overdose causes renal tubular obstruction due to dye precipitation, leading to acute kidney injury [1]
- Subacute toxicity: Repeated administration of Evans Blue (10 mg/kg/week, IV for 4 weeks) in rats does not induce significant hepatotoxicity (ALT/AST levels normal) but causes mild renal tubular vacuolation in 20% of animals [1] - No systemic inflammation or immunotoxicity is observed at experimental doses (≤20 mg/kg); dye-induced tissue damage is limited to cases of high-dose administration or impaired renal function [1] |
| 参考文献 |
|
| 其他信息 |
Evans blue is an organic sodium salt that is the tetrasodium salt of 6,6'-{(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[diazene-2,1-diyl]}bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate). It is sometimes used as a counterstain, especially in fluorescent methods to suppress background autofluorescence. It has a role as a histological dye, a fluorochrome, a teratogenic agent and a sodium channel blocker. It contains an Evans blue(4-).
An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly. See also: Evans Blue (annotation moved to). Evans Blue is a water-soluble azo dye primarily used as a biological tracer in biomedical research, with no clinical therapeutic applications [1] - Its core application mechanism relies on high albumin binding and inability to cross intact biological barriers, enabling assessment of barrier integrity (e.g., BBB, vascular endothelium, intestinal epithelium) [1] - Evans Blue is also used for mapping tissue perfusion, detecting tumor angiogenesis, and evaluating the efficacy of barrier-protective drugs in preclinical models [1] - In BBB research, Evans Blue is considered a gold standard tracer for quantifying barrier disruption, as its brain penetration directly reflects BBB leakage severity [2] |
| 分子式 |
C34H24N6O14S4.4NA
|
|
|---|---|---|
| 分子量 |
960.81
|
|
| 精确质量 |
959.982
|
|
| CAS号 |
314-13-6
|
|
| 相关CAS号 |
|
|
| PubChem CID |
9409
|
|
| 外观&性状 |
White to off-white solid powder
|
|
| LogP |
10.785
|
|
| tPSA |
404.26
|
|
| 氢键供体(HBD)数目 |
4
|
|
| 氢键受体(HBA)数目 |
20
|
|
| 可旋转键数目(RBC) |
5
|
|
| 重原子数目 |
62
|
|
| 分子复杂度/Complexity |
1790
|
|
| 定义原子立体中心数目 |
0
|
|
| InChi Key |
ATNOAWAQFYGAOY-UHFFFAOYSA-J
|
|
| InChi Code |
InChI=1S/C34H28N6O14S4.4Na/c1-15-11-17(3-7-21(15)37-39-23-9-5-19-25(55(43,44)45)13-27(57(49,50)51)31(35)29(19)33(23)41)18-4-8-22(16(2)12-18)38-40-24-10-6-20-26(56(46,47)48)14-28(58(52,53)54)32(36)30(20)34(24)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4
|
|
| 化学名 |
tetrasodium;4-amino-6-[[4-[4-[(8-amino-1-hydroxy-5,7-disulfonatonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]-5-hydroxynaphthalene-1,3-disulfonate
|
|
| 别名 |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意： 请将本产品存放在密封且受保护的环境中，避免吸湿/受潮。 |
|
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
|
|||
|---|---|---|---|---|
| 溶解度 (体内实验) |
配方 1 中的溶解度: ≥ 2.5 mg/mL (2.60 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。 *生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。 配方 2 中的溶解度: ≥ 2.5 mg/mL (2.60 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。 例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。 *生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。 View More
配方 3 中的溶解度: 2.5 mg/mL (2.60 mM) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0408 mL | 5.2039 mL | 10.4079 mL | |
| 5 mM | 0.2082 mL | 1.0408 mL | 2.0816 mL | |
| 10 mM | 0.1041 mL | 0.5204 mL | 1.0408 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;
3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;
4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。
计算结果:
工作液浓度： mg/mL；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。
(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。
Pomaglumetad (LY404039)
VU 0361737
VU 0364439
利芦噻唑
InvivoChem的所有产品仅用于作科学研究，不面向患者销售
Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1
COA
粤公网安备 44011102003439号
463611831
